Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833754 · ClinicalTrials.gov registry record · Phase 1
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01833754 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 24 participants.
The verdict
NCT01833754, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity profile of romosozumab after a single 210 mg subcutaneous dose in healthy participants and patients with stage 4 renal impairment (RI) or stage 5 RI requiring hemodialysis.
Interventions
- DRUG Romosozumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-04-22 |
| Est. Completion | 2014-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833754
The ClinicalTrials.gov registry entry for NCT01833754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Romosozumab is the first listed.
NCT01833754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833754 about?
NCT01833754 is a clinical study titled "Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis". The purpose of this study is to evaluate the safety, tolerability, and immunogenicity profile of romosozumab after a single 210 mg subcutaneous dose in healthy participants and patients with stage 4 renal impairment (RI) or stage 5 RI requiring hemodialysis.
What is the current status of trial NCT01833754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-04-22. Estimated completion is 2014-02-19.
What interventions are being tested in trial NCT01833754?
The interventions under investigation include: Romosozumab (DRUG).
Who is sponsoring clinical trial NCT01833754?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.